Europe Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2030

Medical Devices
Published Report
Dec 2022
Europe
350 Pages
No of Tables: 293
No of Figures: 42

Europe Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales) - Industry Trends and Forecast to 2030.

Europe Lung Cancer Diagnostics Market Analysis and Insights

The Europe lung cancer diagnostics market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. Increasing lung cancer diagnosis and development research is further projected to boost market growth. However, difficulties in lung cancer screening techniques might hamper the growth of the Europe lung cancer diagnostics market in the forecast period.

Increasing healthcare expenditure on cancer diagnosis and treatment is expected to give opportunities to the market to enhance the treatment. However, the high cost of testing and strict regulations and standards for the approval and commercialization of cancer diagnostic products may challenge market growth.

The Europe lung cancer diagnostics market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that the Europe lung cancer diagnostics market will grow at a CAGR of 13.3% during the forecast period of 2023 to 2030.

Report Metric	Details
Forecast Period	2023 to 2030
Base Year	2022
Historic Years	2021 (Customizable to 2020 - 2015)
Quantitative Units	Revenue in USD Million, Pricing in USD
Segments Covered	By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales)
Countries Covered	Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe
Market Players Covered	F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott, Quest Diagnostics Incorporated, Biodesix, Amoy Diagnostics Co., Ltd., Bio-Rad Laboratories, Inc., Biocartis, Boditech Med Inc., Danaher, Vela Diagnostics, DiaSorin S.p.A., Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation), 20/20 Gene Systems, Guardant Health, Inc., Inivata Ltd., LalPathLabs.com, LungLife AI, Inc., MedGenome, Myriad Genetics, Inc., NeoGenomics Laboratories, NanoString, Nanoentek, Oncocyte Corporation, PerkinElmer Inc., PlexBio, QIAGEN, Siemens Healthcare GmbH, and Veracyte, Inc. among others

Market Definition

Cancer begins in the lungs and most often occurs in people who smoke. Two major types of lung cancer are non-small cell lung cancer and small cell lung cancer. Causes of lung cancer include smoking, second-hand smoke, exposure to certain toxins, and family history.

Symptoms include a cough (often with blood), chest pain, wheezing, and weight loss. These symptoms often don't appear until the cancer is advanced. Treatments vary but may include surgery, chemotherapy, radiation therapy, targeted drug therapy, and immunotherapy.

Europe Lung Cancer Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

Increasing early diagnosis of lungs cancer

Machine learning could revolutionize early cancer diagnosis, which trains computers to see patterns in complex data. Tools include assessments of common health data, medical imaging, biopsy samples, and blood tests to help in early diagnosis and risk stratification. In many tumor types, the likelihood of undergoing successful therapy increases with an early cancer diagnosis. One important strategy is to assess patients at risk who do not exhibit symptoms and respond quickly and appropriately to those who do.

The likelihood of successfully treating cancer is considerably increased by early identification. The two elements of early cancer detection are screening and early diagnosis (or downstaging). While screening consists of evaluating healthy individuals to find those who have cancer before any symptoms occur, early diagnosis focuses on identifying symptomatic patients as early as feasible.

Detection of early-stage cancers often limited by high false positives and poor sensitivity

The creation of non-invasive tests that can quickly and reliably identify whether and where in the body a person has early-stage cancer is one of the most promising areas of cancer prevention research. And not just one cancer but a variety of cancers. On this front, significant advancements have been made in recent years. Several multi-cancer early detection (MCED) tests are currently under development, and they are designed to screen for multiple cancer types in otherwise healthy individuals simultaneously. However, detecting early-stage cancer is a challenge as it comes with many barriers, such as high false positives or poor sensitivity. Many cases of poor diagnostics sensitivity lead to a patient's life at risk. The high false positives are also one of the causes of cancer advancing to late stages or advanced stages.

Thus, the detection of early-stage cancers is often limited by high false positives, and sometimes poor sensitivity may act as a major restraining factor for the growth of the Europe lung cancer diagnostics market.

Rise in healthcare expenditure for cancer diagnosis and treatment

Across the globe, research and development activities are escalating owing to the public health expenditure with economic performances. Whereas the healthcare industry ranks second among all industries when it comes to the amount spent on healthcare. Rising healthcare expenditure can result in better provision of research and development opportunities. It is anticipated to increase the demand for lung cancer diagnostics. Increasing the healthcare expenditure for cancer treatment also helps the patient take hassle-free advanced diagnostics and treatment for fast recovery. The spending on healthcare is made up of the combination of out-of-pocket payments (people paying for their care), government expenditure, and sources. It also includes health insurance and activities by non-governmental organizations. This increasing healthcare expenditure for cancer treatment is an opportunity to grow the market's demand.

Lack of skilled and certified professionals

The requirement of skilled and certified professionals is a big restraint for cancer diagnostics. The demand for cancer diagnostic is increased due to increasing cases of cancer disease in the globe, but the fewer number of skilled professionals present in the diagnostic center is hampering the growth of the market.

The instruments, methods, and procedures of cancer diagnosis have been advanced, but there are certain gaps in standardization, equalization, and knowledge. Technicians face technical training gaps related to problems and adapt advanced methods safely to perform procedures efficiently. In cancer diagnostics, skilled professionals are highly needed for method development, validation, operation, and troubleshooting activities.

A cancer diagnosis is a dynamic component in today's complex time, providing patients with essential information for diagnosing, preventing, treating, and managing their cancer disease. The requirement for trained staff is a big issue for the Europe lung cancer diagnostics market. Due to the lack of skilled and certified professionals, end users cannot install advanced products for a cancer diagnosis; this may challenge the growth of the Europe lung cancer diagnostics market.

Post-COVID-19 Impact on Europe Lung Cancer Diagnostics Market

The high burden of COVID-19 on healthcare systems around the world has raised concerns among medical oncologists about the impact of COVID-19 on lung cancer diagnosis and treatment. We investigated the impact of COVID-19 on lung cancer diagnosis and treatment before and after the COVID-19 era in this retrospective cohort study. During the pandemic, new lung cancer diagnoses decreased by 34.7% with slightly more advanced stages of the disease, and there was a significant increase in radiosurgery as the first definitive treatment and a decrease in systemic treatment and surgery compared to the pre-COVID-19 era. Compared to pre-COVID-19 times, there was no significant delay in starting chemotherapy and radiation treatment during the pandemic.

During the pandemic, however, we observed a delay in lung cancer surgery. COVID-19 appears to have significantly impacted lung cancer patients' diagnoses and treatment patterns at our lung cancer center. Many oncologists are concerned that the number of newly diagnosed lung cancer patients will rise in the coming year. This research is still ongoing, and more information will be gathered and analyzed to understand better the overall impact of the COVID-19 pandemic on our lung cancer patient population.

Recent Developments

In October 2022, Quest Diagnostics announced a new chapter of the partnership with Decode Health. This partnership has aided the business in decreasing the time and expense involved in creating fresh diagnostic tests and finding new medication targets for various cancers and increased the company's Europe presence
In August 2022, F. Hoffmann-La Roche Ltd. announced the launch of a Digital LightCycler System, a next-generation digital PCR system that helps clinical researchers better understand the nature of a patient's cancer, genetic disease, or infection. This system is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in oncology and infectious diseases

Europe Lung Cancer Diagnostics Market Scope

The Europe lung cancer diagnostics market is categorized into five notable segments based on product type, test type, cancer type, end user, and distribution channel. The growth amongst these segments will help you analyse meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product Type

Instruments
Consumables & Accessories

On the basis of product type, the Europe lung cancer diagnostics market is segmented into instruments, consumables & accessories.

Test Type

Biomarkers Tests
Imaging Test
Biopsy
Blood Test
Others

On the basis of test type, the Europe lung cancer diagnostics market is segmented into imaging test, biomarkers test, biopsy, blood test, and others.

Cancer Type

Non-Small Cell Lung Cancer
Small Cell Lung Cancer

On the basis of cancer type, the Europe lung cancer diagnostics market is segmented into non-small cell lung cancer and small cell lung cancer.

End User

Hospital
Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others

On the basis of end user, the Europe lung cancer diagnostics market is segmented into hospital, associated labs, independent diagnostics laboratories, diagnostic imaging centers, cancer research institutes, and others.

Distribution Channel

Direct Tender
Retail Sales

On the basis of distribution channel, the Europe lung cancer diagnostics market is segmented into direct tender and retail sales.

Europe Lung Cancer Diagnostics Market Regional Analysis/Insights

The Europe lung cancer diagnostics market is analyzed, and market size insights and trends are provided by country, product type, test type, cancer type, end user, and distribution channel, as referenced above.

Some countries covered in the Europe lung cancer diagnostics report Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe.

Germany is expected to dominate the Europe lung cancer diagnostics market due to increasing technology and reliability of healthcare services, which also deliver infotainment services.

The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of European brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Lung Cancer Diagnostics Market Share Analysis

The Europe lung cancer diagnostics market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the Europe lung cancer diagnostics market.

Some players in the Europe lung cancer diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott, Quest Diagnostics Incorporated, Biodesix, Amoy Diagnostics Co., Ltd., Bio-Rad Laboratories, Inc., Biocartis, Boditech Med Inc., Danaher, Vela Diagnostics, DiaSorin S.p.A., Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation), 20/20 Gene Systems, Guardant Health, Inc., Inivata Ltd., LalPathLabs.com, LungLife AI, Inc., MedGenome, Myriad Genetics, Inc., NeoGenomics Laboratories, NanoString, Nanoentek, Oncocyte Corporation, PerkinElmer Inc., PlexBio, QIAGEN, Siemens Healthcare GmbH, and Veracyte, Inc. among others.

SKU-69559

TABLE 1 DIFFERENT TYPES OF CANCER SCREENING TESTS FOR DIFFERENT TYPES OF CANCERS

TABLE 2 LUNG CANCER RATES

TABLE 3 APPROVED DIAGNOSTICS OF LUNGS CANCER

TABLE 4 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 5 EUROPE INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 6 EUROPE IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 7 EUROPE BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 8 EUROPE PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 9 EUROPE CONSUMABLES & ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 EUROPE CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 11 EUROPE KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 12 EUROPE REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 13 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 14 EUROPE IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 EUROPE IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 16 EUROPE BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 EUROPE BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 18 EUROPE BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 EUROPE BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 20 EUROPE BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 EUROPE BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 22 EUROPE OTHERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 24 EUROPE NON-SMALL CELL LUNG CANCER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 EUROPE SMALL CELL LUNG CANCER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 27 EUROPE HOSPITAL IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 EUROPE ASSOCIATED LABS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 EUROPE INDEPENDENT DIAGNOSTIC LABORATORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 EUROPE DIAGNOSTIC IMAGING CENTERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 EUROPE CANCER RESEARCH INSTITUTES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 EUROPE OTHERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 34 EUROPE DIRECT TENDER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 EUROPE RETAIL SALES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 37 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 38 EUROPE INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 39 EUROPE PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 40 EUROPE IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 41 EUROPE BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 42 EUROPE CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 43 EUROPE KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 44 EUROPE REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 45 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 46 EUROPE BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 47 EUROPE IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 48 EUROPE BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 49 EUROPE BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 50 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 51 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 52 EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 53 GERMANY LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 54 GERMANY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 55 GERMANY PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 56 GERMANY IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 57 GERMANY BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 58 GERMANY CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 59 GERMANY KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 60 GERMANY REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 61 GERMANY LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 62 GERMANY BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 63 GERMANY IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 64 GERMANY BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 65 GERMANY BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 66 GERMANY LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 67 GERMANY LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 68 GERMANY LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 69 U.K. LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 70 U.K. INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 71 U.K. PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 72 U.K. IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 73 U.K. BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 74 U.K. CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 75 U.K. KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 76 U.K. REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 77 U.K. LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 78 U.K. BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 79 U.K. IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 80 U.K. BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 81 U.K. BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 82 U.K. LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 83 U.K. LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 84 U.K. LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 85 FRANCE LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 86 FRANCE INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 87 FRANCE PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 88 FRANCE. IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 89 FRANCE BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 90 FRANCE CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 91 FRANCE KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 92 FRANCE REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 93 FRANCE LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 94 FRANCE BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 95 FRANCE IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 96 FRANCE BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 97 FRANCE BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 98 FRANCE LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 99 FRANCE LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 100 FRANCE LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 101 ITALY LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 102 ITALY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 103 ITALY PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 104 ITALY IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 105 ITALY BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 106 ITALY CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 107 ITALY KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 108 ITALY REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 109 ITALY LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 110 ITALY BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 111 ITALY IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 112 ITALY BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 113 ITALY BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 114 ITALY LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 115 ITALY LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 116 ITALY LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 117 SPAIN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 118 SPAIN INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 119 SPAIN PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 120 SPAIN IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 121 SPAIN BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 122 SPAIN CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 123 SPAIN KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 124 SPAIN REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 125 SPAIN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 126 SPAIN BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 127 SPAIN IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 128 SPAIN BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 129 SPAIN BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 130 SPAIN LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 131 SPAIN LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 132 SPAIN LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 133 RUSSIA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 134 RUSSIA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 135 RUSSIA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 136 RUSSIA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 137 RUSSIA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 138 RUSSIA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 139 RUSSIA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 140 RUSSIA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 141 RUSSIA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 142 RUSSIA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 143 RUSSIA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 144 RUSSIA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 145 RUSSIA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 146 RUSSIA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 147 RUSSIA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 148 RUSSIA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 149 NETHERLANDS LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 150 NETHERLANDS INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 151 NETHERLANDS PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 152 NETHERLANDS IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 153 NETHERLANDS BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 154 NETHERLANDS CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 155 NETHERLANDS KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 156 NETHERLANDS REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 157 NETHERLANDS LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 158 NETHERLANDS BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 159 NETHERLANDS IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 160 NETHERLANDS BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 161 NETHERLANDS BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 162 NETHERLANDS LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 163 NETHERLANDS LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 164 NETHERLANDS LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 165 SWITZERLAND LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 166 SWITZERLAND INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 167 SWITZERLAND PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 168 SWITZERLAND IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 169 SWITZERLAND BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 170 SWITZERLAND CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 171 SWITZERLAND KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 172 SWITZERLAND REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 173 SWITZERLAND LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 174 SWITZERLAND BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 175 SWITZERLAND IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 176 SWITZERLAND BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 177 SWITZERLAND BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 178 SWITZERLAND LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 179 SWITZERLAND LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 180 SWITZERLAND LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 181 TURKEY LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 182 TURKEY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 183 TURKEY PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 184 TURKEY IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 185 TURKEY BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 186 TURKEY CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 187 TURKEY KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 188 TURKEY REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 189 TURKEY LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 190 TURKEY BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 191 TURKEY IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 192 TURKEY BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 193 TURKEY BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 194 TURKEY LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 195 TURKEY LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 196 TURKEY LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 197 BELGIUM LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 198 BELGIUM INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 199 BELGIUM PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 200 BELGIUM IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 201 BELGIUM BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 202 BELGIUM CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 203 BELGIUM KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 204 BELGIUM REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 205 BELGIUM LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 206 BELGIUM BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 207 BELGIUM IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 208 BELGIUM BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 209 BELGIUM BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 210 BELGIUM LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 211 BELGIUM LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 212 BELGIUM LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 213 POLAND LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 214 POLAND INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 215 POLAND PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 216 POLAND IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 217 POLAND BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 218 POLAND CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 219 POLAND KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 220 POLAND REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 221 POLAND LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 222 POLAND BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 223 POLAND IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 224 POLAND BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 225 POLAND BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 226 POLAND LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 227 POLAND LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 228 POLAND LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 229 DENMARK LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 230 DENMARK INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 231 DENMARK PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 232 DENMARK IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 233 DENMARK BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 234 DENMARK CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 235 DENMARK KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 236 DENMARK REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 237 DENMARK LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 238 DENMARK BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 239 DENMARK IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 240 DENMARK BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 241 DENMARK BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 242 DENMARK LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 243 DENMARK LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 244 DENMARK LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 245 SWEDEN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 246 SWEDEN INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 247 SWEDEN PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 248 SWEDEN IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 249 SWEDEN BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 250 SWEDEN CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 251 SWEDEN KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 252 SWEDEN REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 253 SWEDEN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 254 SWEDEN BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 255 SWEDEN IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 256 SWEDEN BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 257 SWEDEN BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 258 SWEDEN LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 259 SWEDEN LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 260 SWEDEN LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 261 NORWAY LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 262 NORWAY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 263 NORWAY PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 264 NORWAY IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 265 NORWAY BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 266 NORWAY CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 267 NORWAY KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 268 NORWAY REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 269 NORWAY LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 270 NORWAY BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 271 NORWAY IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 272 NORWAY BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 273 NORWAY BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 274 NORWAY LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 275 NORWAY LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 276 NORWAY LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 277 FINLAND LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 278 FINLAND INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 279 FINLAND PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 280 FINLAND IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 281 FINLAND BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 282 FINLAND CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 283 FINLAND KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 284 FINLAND REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 285 FINLAND LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 286 FINLAND BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 287 FINLAND IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 288 FINLAND BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 289 FINLAND BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 290 FINLAND LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 291 FINLAND LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 292 FINLAND LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 293 REST OF EUROPE LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

At what growth rate will the market be projected to grow during the forecast period of 2023 to 2030?

The Europe Lung Cancer Diagnostics Market is projected to grow at a CAGR of 13.3% during the forecast period by 2030.

Which market segments are covered in this report?

The Europe Lung Cancer Diagnostics Market is segmented on the basis of product type, test type, cancer type, end user, and distribution channel.

Who are the major players operating in the market?

The major players in the Europe Lung Cancer Diagnostics Market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott, Quest Diagnostics Incorporated, Biodesix, Amoy Diagnostics Co., Ltd., Bio-Rad Laboratories, Inc., Biocartis, Boditech Med Inc., Danaher, etc.

Which countries data are covered in the report?

The countries covered in the Europe Lung Cancer Diagnostics Market are Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe.

BROWSE RELATED Press Release

Increasing Private and Public Expenditure for the Development of Healthcare Infrastructure is driving the Growth of the Market

Abbott, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated are dominating the North America Non-Small Cell Lung Cancer Diagnostics Market in 2021

Empowering Precision Lung Cancer Diagnostics: A Promising Future of Innovation and Personalized Care

Free Sample Report

CHOOSE LICENCE TYPE

Enterprise User 4200.00
Single User 3500.00
DBMR Factbook 2000.00
DBMR Prime 5500.00
DBMR Supreme 7500.00

Buy Now

Request for TOC Speak to Analyst Inquire Before Buying Free Sample Report

Advance Formative Research Customization Request for bulk Reports

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.